ABSTRACT -Social anxiety disorder (SAD) is a marked and persistent fear of doing almost everything in front of people due to concerns about being judge by others. An up-to-date review is needed in order to reach a practical judgement of all psychopharmacological data. Case reports, open and double-blind trials with SAD were described and commented upon from a clinical point of view. The MEDLINE system was searched from 1975 to 2001. The references from the selected papers were also used as a source. MAOIs (fenelzine, tranylcypromine), reversible monoamino oxidase-A inhibitors (moclobemide, brofaromine), SSRIs (paroxetine, sertraline, fluoxetine, fluvoxamine) and some other antidepressants (venlafaxine, nefazodone) have proven effective in several studies with various methodologies. The MAOIs have more serious adverse effects and the SSRIs have the best tolerance. SSRIs are efficacious and the first choice of treatment.
The primary characteristic of social anxiety disorder (SAD) or social phobia 1,2 is a persistent and excessive fear of being criticized and judged in performance or social interactive situations. SAD is a new expression for social phobia emphasizing the anxiety symptoms and not just the avoidance 1 . People who suffer from SAD have the feeling that they will be judged negatively in situations where they have to perform activities while being observed, with fear of feeling embarrassed or of being humiliated. They are even more afraid or embarrassed when someone notices their symptoms of anxiety 2 . The fear of these situations and the anxiety provoked when they must be confronted is so intense that it makes the individual avoid public activities where such exposition may occur. This is an inadequate answer to certain stimuli, as a result of the presence somatic symptoms and their intensity and duration.
Pacients may report symptoms that are common to anxiety, like palpitations, tremblings, sweating, muscular tension, mouth dryness, nausea, diarrhoea or headache. However, some pacients complain mainly of exaggerated fear and self-criticism, which prevents them from interacting normally. There are two subtypes of SAD: the circumscribed one (symptoms in just one specific situation) and the generalized (symptoms in all social situations). This clinical difference has some therapeutic implications. The treatment of choice may be the association of psychopharmacotherapy and psychotherapy 2 . We describe below the main clinical-phamacological studies with antidepressants in SAD. The re-vision was made through the MEDLINE system, with the key words: SAD, social phobia, antidepressant, psychopharmacology, benzodiazepines, tricyclic, monoamine oxidase inhibitor, selective serotonine reuptake inhibitors, treatment. The period of the research was between 1975 and 2001. The references of the selected works were used as another source of bibliographic consultation.
Monoamine Oxidase Inhibitors (MAOIs)
In the 80s clinical studies with homogeneous groups of social phobics were carried out. The efficacy of the MAOIs, such as tranylcypromine and phenelzine, in the treatment of SAD patients without comorbid depression, has been proved by open 3, 4 and double-blind studies 5, 6 ( Table 1) . The first open study 3 used phenelzine in 11 SAD patients. A big improvement was verified in 7 cases treated with 45 and 60 mg/day doses for 7 months. In another open study 4 tranylcypromine was tested in 29 patients. The treatment duration was 1 year, with 40 and 60 mg/ day doses. After the exclusion of 3 patients that abandoned the treatment in the beginning, a big improvement could be observed in 62% and a moderate improvement in 17% of the sample. The common side effects noticed in the studie 3, 4 were: orthostatic hypotension, insomnia, decreased libido, fatigue, nausea, diarrhoea, irritability and increase in psychomotor activity. These side effects had a tendency to disappear with the maintenance of the treatment and adjustment of the dose. The studies also demonstrated that accentuated degrees of improvement could be observed only after three months of treatment. This observation strenghts the clinical impression that studies using the double-blind method must have a minimal duration of 4 months; distinguishing SAD patients from patients with depression or panic disorder.
The first double-blind study with patients with SAD 5 compared phenezine and atenolol with placebo in the treatment of 74 patients with SAD. The average dose was 76 mg/day for phenelzine and 98 mg/day for atenolol.
During the 16 week treatment, about 2/3 of the patients treated with phenelzine had significant improvement, whereas less than 1/3 had the same improvement in the groups treated with atenolol and placebo. The patients treated with MAOI, in spite of dietetic restrictions and high risk of serious side effects, had an important reduction in social anxiety and avoidance, performing more comfortably their social and professional activities. It was observed that patients suffering from generalized SAD had better results with phenelzine. Moclobemide, a reversible inhibitor of MAO -A (RIMA), appeared as a hope in the treatment of SAD. Its profile of side effects and its safety in the interaction with food and other pharmacs brought an incentive to the research in the area 7 . However, the results are conflicting about its efficacy ( Table 2) .
The first double-blind study with moclobemide 6 compared it with placebo and phenelzine. Moclobemide presented intermediary results (78% improvement) in the first 8 weeks, the same as the phenelzine (more than 80% improvement) in 16 weeks. Both drugs were significantly superior to the placebo in all mensurations. The maximum dose of moclobemide was of 600 mg/day, and of phenelzine 90 mg/day. Moclobemide was greatly superior to the fenelzine regarding tolerance of side effects.
A negative result was observed 8 in a double-blind study with placebo. 77 SAD patients were treated with moclobemide or placebo after demonstrating no response to a week with placebo treatment. The patients were treated for 8 weeks, and to the ones that had any small improvement another 8 weeks of treatment were offered. It could not be observed any difference between the two groups, with only 7 (17,5%) patients improving in the moclobemide group against 5 (13,5%) in the placebo group. In this trial there was a very low response to moclobemide and to placebo.
Moclobemide was also analyzed in a long open, naturalistic and introspective study 9 . 93 patients suffering from generalized and circumscribe SAD with and different comorbidities were treated with moclobemide for 2 years. The average dose was 712 mg/day. 59 patients showed Placebo significant symptomatological improvement and completed the 2 years treatment. After a minimum period of one month without the drug, 88% of the patients showed the symptoms again and were treated for 2 more years with the same therapeutic response. A follow-up after the 6 to 24 months of treatment demonstrated that 15,8% were without any kind of treatment, 28,1% were using moclobemide again, 10,6% were using other medicines and 8,8% were in psychotherapy. The patients that did not improve with moclobemide presented almost always alcohol abuse (36,9%) and severe or moderate SAD. Alcohol abuse was a strong predictor of absence of therapeutic response. An American multicenter study with moclobemide 10 observed a poor drug and a high placebo response. After a week using placebo, the patients were randomically alocated in 6 groups: placebo or doses of 75, 150, 300, 600 or 900 mg/day of moclobemide. After 12 weeks it was observed a similar answer from all the groups, with the good response of 35% of the patients using 900 mg/ day of moclobemide and 33% using placebo. In another international multicentric study with moclobemide 11 , a moderate opposite result was observed. 578 patients with SAD, after using placebo for a week, were treated for 12 weeks with moclobemide 300 mg/day or 600 mg/day or placebo. It was reported a clear relation dose-therapeutic response, with the 600 mg/day dose of moclobemide being significantly more efficient than the other two groups. The smaller dose of moclobemide 300 mg/day was also better than the placebo in all mensurations, but did not attain statistical significance. The most commom side effect was insomnia.
Another RIMA, brofaromine, has been showing good therapeutic results [12] [13] [14] (Table 2 ). The first double-blind trial with brofaromine 12 in 30 patients with SAD was a 12-week placebo controlled design. A significant improvement was seen in 80% of the brofaromine group (150mg daily) but not on placebo. Most common side effect was middle sleep disturbance. During a follow-up period of 12 weeks a further improvement was found in patients treated with brofaromine. In another double-blind trial 13 , 77 patients were randomized to treatment with brofaromine (n=37) or placebo (n=40) for 12 weeks. In the brofaromine group, 78% of the patients scored much or very much improved on the Clinical Global Impression scale, compared with 23% in the placebo group. The drug group improved further during 9-month follow-up treatment period, whereas 60% of the placebo responders who continued long-term treatment relapsed. The most frequent side effects in the brofaromine group were sleep disturbances, dry mouth and nausea.
Brofaromine was also analyzed in an another doubleblind study with placebo 14 . After one week of placebo, 102 patients were treated for 10 weeks (50 with placebo and 52 with brofaromine). Brofaromine started with a 50 mg/day dose and was progressively increased up to 150 mg/day according to therapeutic response. Brofaromine was significantly superior to placebo in the utilized evaluation methods. 14 patients using brofaromine dropped from the study precociously, 11 due to adverse effects. The most commom adverse effects were insomnia, dizziness, dry mouth, anorexia and shaking. The classic MAOIs are drugs that affect several neurotransmission systems. They have strong noradrenergic, serotoninergic and dopaminergic actions and serious side effects 3, 4, 7 . This can explain their efficacy but also their very low tolerance.
Despite their proved efficacy in clinical controlled studies against placebo, the MAOIs, especially phenelzine or its congeneric tranylcypromine, cannot be considered as first choice treatments for SAD. They may induce serious hypertension crisis, with irreversible effects because of interactions with sympathomimetic substances.
It was said, about the treatment of panic disorder 7 , that these medicaments, in spite of being more efficient, are not the most recommended. In the case of SAD this should be even more stressed. Despite being very incapacitating, SAD is chronic and the symptoms come to surface only in determined situations. Using these drugs would submit the patient to the risks of serious side effects for many years, even during the assymptomatic periods. The most worrisome accidents are endogenous or spontaneous hypertensive crisis that happens with no apparent reason. One likely explanation this kind of hypertensive crisis is the possibility that bacterial metabolism in the bowels produces tyramine 4, 7 .
Tricyclic Antidepressants Clormipramine has some efficacious report 15 and also as inefficient in 6 individuals with SAD 4 . It was a case report of the 6 poor response patients. The state of the patients became worse due to light shaking in the hands, induced by the tricyclic. The patients were treated with doses between 175 and 250 mg/day for 3 months. After this period of time, the patients were treated with tranylcypromine, showing good results.
Imipramine was evaluated in an open study 16 with a sample of 15 patients treated for 8 weeks. Only 9 patients finished the treatment, and all the ones that dropped out, did it because of the side effects. Among the patients that finished the treatment the therapeutic response was very small, about 20%.
Nefazodone
The antidepressive nefazodone is a serotonin-reuptake inhibitor and a 5-HT2 receptor agonist. An open study 17 observed a positive response in 3 among 5 patients with SAD, and 3 individuals had comorbidity with dyshymic disorder. Another open clinical study was carried out 18 with a sample of 23 patients with generalized SAD. The duration of the treatment was 12 weeks. 21 patients finished the treatment, and 16 (69,6%) had a good or moderate response.
Venlafaxine
Venlafaxine is an antidepressant drug that inhibits noradrenaline and serotonin reuptake. It was described as potentially efficient in an open study 19 with 9 patients, with 8 of them being considered refractory to serotoninspecific reuptake inhibitors (SSRIs). A larger trial 20 aimed to evaluate the clinical response to venlafaxine in 12 patients who were non-responders to selective serotonin reuptake inhibitors. The duration of the study was 15 weeks using open flexible doses ranging from 112.5 to 187.5 mg/day. Venlafaxine significantly reduced the avoidant behaviour the specific sociophobic aspects. The main side-effects being nausea, headache and anxiety.
Serotonin-Specific Reuptake Inhibitors (SSRIs)
SSRIs have been largely used in SAD (Table 3 ). .luoxetine was tested in 16 social phobia patients with an open method for 12 weeks 21 . The treatment started with 20 mg/day and was increased according to the efficacy and 22 . It was also described as efficient 23 in doses of up to 200 mg/day during 12 weeks with 11 patients. Only 7 patients finished the study, and 5 responded favorably, with an average dose of 170 mg/day. The 4 patients that abandoned the study did it because of adverse effects and loss of the interest to continue with the treatment. Sertraline was analyzed in SAD 24 with a doube-blind method with cross-over in 12 patients. Initially they were treated for 10 weeks with sertraline in doses between 50 and 200 mg/ day. Consecutivelly, they were treated for 10 weeks with placebo. The results were statistically favorable to sertraline. It is interesting that the patients were analyzed by examinators and by computer analyzed self-evaluation scales. There was no difference between the two evaluation methods, but the patients preferred the evaluation done by the computer.
Van Amering et al. 25 evaluated sertraline vs. placebo in 204 generalized SAD patients for a 20-week doubleblind study. The dosing was flexible up to a maximum of 2000mg/day. Significantly more the 134 patients given sertraline (n=71 [53%]) than of the 69 patients receiving placebo (n=20[29%]) were considered responders according to their CGI improvement scores at the end of treatment.
A positive result was observed in a case report with 3 patients taking citalopram 26 . All the 3 patients had their state improved after more than 8 weeks of treatment.
In another trial double-blind trial 27 , fluvoxamine (150 mg daily) was compared to placebo in 30 patients during a 12-week period. A substantial improvement was observed in 7 (46%) patients on fluvoxamine and in 1 (7%) on placebo. Statistically significant effects were seen on measures of SAD treated with fluvoxamine compared to placebo. The level of phobic avoidance decreased also but the difference at endpoint between fluvoxamine and placebo failed to reach statistical significance.
The fluvoxamine 28 was analyzed with a double-blind method with placebo in 92 social phobic patients treated for 12 weeks. The generalized subtype was present in 91,3% of the patients. The average dose of fluvoxamine was 202 mg/day. There was little response (42,9%) but it was significantly superior to the placebo (22,7% ).
An open label trial of fluvoxamine 29 was conducted to evaluate its efficacy safety in SAD and to assess physiological changes that may accompany treatment. 15 nondepressed patients entered the sudy. 10 patients completed an active 6 week treatment period. There were 3 drop-out due to side effects: drowsiness (n=2) and nausea (n=1). Clinical benefits were still evident at a short follow-up 1 week after drug discontinuation. Neither physiological effects nor plasma drug concentration correlated with clinical change. .luvoxamine appeared to be effective and well tolarated in completers.
The first report of clinical observation with the efficacy of paroxetine against SAD 30 stimulated the realization of controlled studies. Paroxetine was utilized in 18 generalized SAD patients treated 31 with an open method for 12 weeks. All the patients finished the research; and 15 (83.3%) responded favorably. Another open study with paroxetine 32 for 11 weeks analyzed 36 patients with generalized SAD. The average dose was 47.9% mg/day. 23 (77%) patients were considered as showing a significant symptomatological improvement. At the end of this initial stage, 16 patients were randomized for more 12 weeks of double-blind treatment with paroxetine on a fixed dose or placebo. Only 1 patient showed a return of the symptoms in the paroxetine group, against 5 in the placebo group.
A large North American multicenter trial with paroxetine in SAD 33 compared it to placebo in a 12-week double-blind condition. 183 patients were randomly selected and the daily dosage of paroxetine was 20 mg with increases of 10 mg/day weekly (flexible dosing to a maximum of 50 mg/day). 55.0% of 91 persons taking paroxetine and 23.9% of 92 persons taking placebo were much or very much improved at the end of treatment.
CONCLUSION
The antidepressants seem to be the group of choice for SAD patients. When we take into account the controlled studies, the first choice of treatment for SAD will be the SSRIs antidepressants. They have been widely studied and have shown good therapeutic results and tolerance.
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